Remove FDA Remove Food and Drug Administration Remove Prospecting Remove Sales
article thumbnail

FDA Grants ExThera Multiple Breakthrough Device Designations for its Seraph® 100 Filter

Legacy MEDSearch

Food and Drug Administration (FDA), for its Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). It additionally signals that the FDA is already thinking about future pandemic preparedness, something we are keen to partner on with them and the medical community.” “I

FDA 52
article thumbnail

Empirical Spine Completes Full Premarket Approval (PMA) Submission to FDA for Limiflex™ Dynamic Sagittal Tether™

Legacy MEDSearch

Food & Drug Administration (FDA) submission process for the LimiFlex Dynamic Sagittal Tether (DST). The device previously received the FDA’s Breakthrough Designation for its potential to provide significant advantages over currently approved spinal stabilization technologies. Empirical Spine, Inc.,

FDA 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First Light Field-Enabled Spine Surgery Navigation Platform, Proprio Paradigm™, Receives FDA Clearance

Legacy MEDSearch

Food and Drug Administration (FDA). “As a clinician, the prospect of accessing a more complete set of data intraoperatively is very exciting.” Proprio , a Seattle-based medical technology company, today announced its surgical navigation platform, Paradigm, has received 510(k) clearance from the U.S.

FDA 52
article thumbnail

Blueprint Medicines announces financing partnerships for $1.25bn

Pharmaceutical Technology

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. Ayvakit has received the US Food and Drug Administration (FDA) approval to treat advanced systemic mastocytosis in adults.

article thumbnail

Watch These 4 Large Drug Stocks Amid the Booming Industry

Contrarian Sales Techniques

The biotechnology and drug sectors performed well in the second half of 2022 after struggling in the first six months. Despite the uncertainty surrounding the global economy, the drug and biotechnology sectors have continued to perform well in the second half of 2022. This can lead to significant losses for large companies.

article thumbnail

BioVentrix® Closes $48.5 Million Series A Financing

Legacy MEDSearch

Food and Drug Administration for an Expanded Access Program following the successful completion of enrollment in ALIVE, a prospective, multi-center, dual-arm pivotal study. The Company is preparing to submit the PMA application to the FDA later this year. BioVentrix recently received approval from the U.S.

article thumbnail

Centinel Spine® Completes Enrollment in First-of-its-Kind 2-Level IDE Trial Evaluating prodisc® C Match-the-Disc™ Cervical TDR System

Legacy MEDSearch

The prospective, randomized clinical trial is designed to evaluate the safety and effectiveness of the pro disc C Vivo and pro disc C SK system by comparing it with an approved TDR product as a control for 2-level indications, making it the first and only of its kind with two investigational devices and a TDR control.